# GSK is assessing mocertatug rezetecan as a treatment for platinum-resistant ovarian cancer and endometrial cancer.

*biotech · news · 2026-04-13 · MarketScreener*

## Key points

- GSK reported a 62% response rate in platinum-resistant ovarian cancer with mocertatug rezetecan.
- The drug showed a 67% response rate in recurrent or advanced endometrial cancer at highest doses.
- GSK set the recommended phase-three trial dose at 5.8 milligrams per kilogram.
- Five pivotal global phase III trials for mocertatug rezetecan will begin later this year.

**Companies:** GSK PLC
**Countries:** United Kingdom, China

[Read the full story on MarketScreener](https://www.marketscreener.com/news/gsk-posts-encouraging-data-for-endometrial-and-ovarian-cancer-drug-ce7e50d9d18cf027)

---

Canonical: https://newsio.io/n/c275cae8-3086-4ad9-8335-79915afd1bad/gsk-is-assessing-mocertatug-rezetecan-as-a-treatment-for-platinum-resistant-ovar
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works